All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F22%3A73612594" target="_blank" >RIV/61989592:15110/22:73612594 - isvavai.cz</a>

  • Result on the web

    <a href="https://jnm.snmjournals.org/content/early/2022/02/17/jnumed.121.263132" target="_blank" >https://jnm.snmjournals.org/content/early/2022/02/17/jnumed.121.263132</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2967/jnumed.121.263132" target="_blank" >10.2967/jnumed.121.263132</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer

  • Original language description

    Prostate-specific membrane antigen (PSMA)–negative neuroendocrine prostate cancer (PCa) is a subtype of PCa likely to be lethal, with limited clinical diagnostic and therapeutic options. High expression of neurotensin receptor subtype 1 (NTR1) is associated with neuroendocrinedifferentiation of PCa, which makes NTR1 a potential target for neuroendocrine PCa. In this study, the NTR1-targeted tracer 68Ga-DOTA-NT-20.3 was synthesized, and its affinity to androgen-dependent (LNCap) and androgen-independent (PC3) xenografts was determined. Methods: 68Ga-DOTA-NT-20.3 was labeled using an automated synthesizer module, and its stability, labeling yield, and radiochemical purity were analyzed by radio–high-performance liquid chromatography. Receptor binding affinity was evaluated in NTR1-positive PC3 cells by a competitive binding assay. The biodistribution of 68Ga-DOTA-NT-20.3 in vivo was evaluated in PC3 and LNCap xenografts by small-animal PET imaging. NTR1 expression was identified by immunohistochemistry and immunofluorescence evaluation. Results: 68 Ga-DOTA-NT-20.3 was synthesized successfully, with a yield of 88.07% 61.26%, radiochemical purity of at least 99%, and favorable stability. The NTR1 affinity (half-maximal inhibitory concentration) for 68 Ga-DOTA-NT-20.3 was 7.59 6 0.41 nM. Small-animal PET/CT of PC3 xenograft animals showed high-contrast images with intense tumor uptake, which revealed specific NTR1 expression. The tumors showed significant radioactivity (4.95 6 0.67 percentage injected dose per gram of tissue [%ID/g]) at 1 h, which fell to 1.95 6 0.17 %ID/g (P , 0.01, t 5 8.72) after specific blockage by neurotensin. LNCap xeno-grafts had no significant accumulation (0.81 6 0.06 %ID/g) of 68 Ga-DOTA-NT-20.3 at 1 h. In contrast, 68 Ga-PSMA-11 was concentrated mainly in LNCap xenografts (8.60 6 2.11 %ID/g), with no significant uptake in PC3 tumors (0.53 6 0.05 %ID/g), consistent with the in vitro immunohistochemistry findings. Biodistribution evaluation showed rapid clearance from the blood and main organs (brain, heart, lung, liver, muscle, and bone), with significantly high tumor-to-liver (4.41 6 0.73) and tumor-to-muscle (12.34 6 1.32) ratios at 60 min after injec-tion. Conclusion: 68 Ga-DOTA-NT-20.3 can be efficiently prepared with a high yield and high radiochemical purity. Its favorable biodistribution and prominent NTR1 affinity make 68 Ga-DOTA-NT-20.3 a potential adiopharmaceutical for the detection of PSMA-negative PCa andidentification of neuroendocrine differentiation.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30224 - Radiology, nuclear medicine and medical imaging

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

  • ISSN

    1619-7070

  • e-ISSN

    1619-7089

  • Volume of the periodical

    63

  • Issue of the periodical within the volume

    9

  • Country of publishing house

    DE - GERMANY

  • Number of pages

    7

  • Pages from-to

    1394-1400

  • UT code for WoS article

    000859967100016

  • EID of the result in the Scopus database

    2-s2.0-85138530690